Abstract: The invention relates to a poly(n-butyl cyanoacrylate) nanoparticle with dual modifications, a drug delivery system comprising the nanoparticle, and a method for preparing the nanoparticle or the drug delivery system. The nanoparticle is modified with a first modifier and a second modifier on the surface, the first modifier is a hydrophilic polymer, and the second modifier is an amino acid and/or a lipid. The invention further relates to a use of the nanoparticle in promoting drug penetration across the blood brain barrier in a subject.

Abstract: The invention involves the pharmaceutical use of honokiol, in particular the use of honokiol in inhibiting medulloblastoma, and it has been experimentally proved that honokiol can inhibit the proliferation and induce cell cycle arrest and apoptosis of medulloblastoma cells; promoting hair growth, and it has been experimentally proved that honokiol can promote hair growth and has no toxic and side effects on liver and kidney; and promoting white hair blackening, and it has been experimentally proved that honokiol can promote white hair blackening and has no toxic side effects on liver and kidney.

Abstract: Provided are a Cryptomeridiol synthase and a coding gene thereof. Also provided are a Cryptomeridiol synthase and a coding gene, a engineered yeast containing the Cryptomeridiol coding gene, and a use of same in plant breeding and biosynthesis. The cDNA full-length sequence of the Cryptomeridiol synthase gene in Tripterygium wilfordii is obtained by means of polymerase chain reaction cloning. Then, by means of synthetic biology, the engineered yeast containing the Cryptomeridiol synthase gene is constructed to realize the production of Cryptomeridiol in the yeast.

Abstract: A cannula plugging device for rehabilitation after tracheotomy relates to the field of medical devices. The cannula plugging device includes a plugging device bracket. An outer wall of the plugging device bracket is fitted with a ring-shaped outer airbag. An inner wall of the plugging device bracket is fitted with a ring-shaped inner airbag. Two inflation tubes connecting the outer airbag and the inner airbag respectively are fitted on the plugging device bracket. The present invention makes the outer airbag and the inner wall of tracheotomy cannula pressed together by inflating the outer airbag. By gradually inflating the inner airbag and adjusting the size of the inner diameter of the lumen, the opening of the trachea gradually changes, so that the patient can gradually adapt to the process of plugging the cannula.

Abstract: This disclosure provides kits and methods for determining whether a subject is suffering from a liver disease, and/or whether the subject will be a responsive to a therapy for a liver disease. The disclosed methods comprise determining the miR profile of exosomes isolated from a body fluid of the subject.

Abstract: Disclosed in the present invention are an edaravone pharmaceutical composition and an application thereof as a sublingual preparation, the pharmaceutical composition containing edaravone or a salt thereof and mannitol. A sublingual administration preparation can avoid the first-pass effect of the liver, and samples feature good stability, convenience of transport and of use, among other advantages.

Abstract: A novel serological target marker GP73 used for diagnosing and identifying a simple fatty liver and steatohepatitis in populations with fatty liver and a detection application method thereof. The serological target marker GP73 and the application thereof can replace golden standard liver puncture to identify and diagnose the simple fatty liver and steatohepatitis in populations with fatty liver, reduce the detection pain of a patient, and have an extremely high clinical application value in clinically identifying and diagnosing the simple fatty liver and steatohepatitis in the populations with fatty liver and assisting the treatment of the simple fatty liver and steatohepatitis.

Abstract: The present invention provides the use of Cimicifugae rhizoma triterpenoid saponin extract, Cimicifugae rhizoma, actein, deoxyactein, or a composition formed by actein and deoxyactein in the preparation of a medicament or a functional health product for autoimmune diseases. The present invention also provides a pharmaceutical composition for autoimmune diseases and a pharmaceutical composition for inhibiting inflammatory cytokines. The invention provides new applications of Cimicifugae rhizoma triterpenoid saponin extract, Cimicifugae rhizoma, actein, deoxyactein, etc., and widens the application field of medicines or functional health products for autoimmune diseases. The raw materials source is plenty, the cost is low, and it has a broad market application value.

Abstract: An active peptide for enhancing the phagocytic functions of retinal pigment epithelium and a use thereof, which belongs to the technical field of preparing drugs for treating retinal neurodegenerative diseases, are described. The amino acid sequence of the active peptide for enhancing the phagocytic functions of retinal pigment epithelium described in the disclosure was as shown in SEQ ID NO.1. The active peptide of the present invention has biological characteristics similar to those of Gas6 full-length proteins, with an effect of enhancing the phagocytic functions of retinal pigment epithelium.

Abstract: Provided are a Cryptomeridiol synthase and a coding gene thereof. Also provided are a Cryptomeridiol synthase and a coding gene, a engineered yeast containing the Cryptomeridiol coding gene, and a use of same in plant breeding and biosynthesis. The cDNA full-length sequence of the Cryptomeridiol synthase gene in Tripterygium wilfordii is obtained by means of polymerase chain reaction cloning. Then, by means of synthetic biology, the engineered yeast containing the Cryptomeridiol synthase gene is constructed to realize the production of Cryptomeridiol in the yeast.

Abstract: Chimeric antigen receptors for efficient and selective in vitro proliferation and uses thereof. Specifically, the present invention provides a CAR-encoding molecule with specific selectivity in vitro. By introducing a humanized selective domain into the molecule, the CAR-positive cells after being infected can be efficiently sorted via a secondary sorting step. Upon exposure to the selective domain-specific antibody, the CAR-transduced immune cells can be selectively expanded; therefore, the ratio of the CAR-positive target cells in the final product is significantly increased, improving the efficiency of preparing CAR gene-modified immune cell products. The present invention provides a more reliable technical support for further promotion and application of such products in clinical practice.

Abstract: A method for increasing the proportion of a central memory T cell (Tcm) subset in a CAR-T cell product includes adding an artificial antigenic epitope in a CAR, and activating a CAR-T by the artificial antigenic epitope, wherein the artificial antigenic epitope does not exist in other domains or segments of the CAR. A method for preparing a CAR-T cell includes: introducing the CAR into a T cell; and culturing the CAR-introduced T cell, and performing specific activation in the culture process. The preparation method can not only increase the proportion of CAR-positive T cells in the product, but also can achieve specific in vitro amplification of the Tcm subset in the CAR-positive T cells, and significantly increases the proportion of Tcm in a final product. Clinical trials show that the CAR-T cells have significantly improved amplification capacity in vivo, and improved clinical safety and effectiveness.

Abstract: A traction apparatus, comprising a clip portion (2) and a traction portion (1), the traction portion containing a closed traction structure (11); the closed traction structure being made from an elastic material; the clip portion comprising a main clip body (23, 25) and a clip arm (24, 26); the main clip body being capable of passing through a biopsy channel (4) of an endoscope (3), the clip arm being capable of clip the closed traction structure. Also disclosed is a traction ring used for the traction apparatus, the traction ring being a single closed traction structure or being formed by connecting several closed traction structures, the traction ring being made from an elastic material.

Abstract: A specific antibody for detecting the blood brain barrier early injury of cerebral ischemic stroke is characterized by specifically identifying KTRRKMDRYDKSNIL in degradation fragments of an occludin protein, but not identifying the full-length occludin protein. Therefore, the antibody can be used for specifically detecting the blood brain barrier early injury of the cerebral ischemic stroke, and can eliminate the influence of the full-length occludin protein in serum on a detection result, so that the specificity and accuracy of detecting the blood brain barrier early injury of the cerebral ischemic stroke are obviously improved.

Abstract: A specific antibody for detecting the blood brain barrier early injury of cerebral ischemic stroke is characterized by specifically identifying specifically identifying DHYETDYTTGGESC in degradation fragments of an occludin protein, but not identifying the full-length occludin protein. Therefore, the antibody can be used for specifically detecting the blood brain barrier early injury of the cerebral ischemic stroke, and can eliminate the influence of the full-length occludin protein in serum on a detection result, so that the specificity and accuracy of detecting the blood brain barrier early injury of the cerebral ischemic stroke are significantly improved.

Abstract: A specific antibody for detecting the blood brain barrier early injury of cerebral ischemic stroke is characterized by only specifically identifying SKLSHIKKMVGDYDR in degradation fragments of an occludin protein, but not identifying the full-length occludin protein. Therefore, the antibody can be used for specifically detecting the blood brain barrier early injury of the cerebral ischemic stroke, and can eliminate the influence of the full-length occludin protein in serum on a detection result, so that the specificity and accuracy of detecting the blood brain barrier early injury of the cerebral ischemic stroke are obviously improved.

Abstract: The invention provides a method and system for health condition analysis based on an elasticity detection device. The method includes: sending, by a client, a health condition analysis request to a cloud server, where the health condition analysis request includes individual attribute identification information of a querier; acquiring, by the cloud server, to-be-analyzed data corresponding to the health condition analysis request from a cloud database storing displacement data of each querier, and conducting data analysis on the to-be-analyzed data to obtain health condition information of the querier; and receiving, by the client, the health condition information of the querier sent by the cloud server. Therefore, by virtue of mass displacement data of mass queriers stored in the cloud server, the querier can conveniently learn his/her health condition in time through the client.

Abstract: The invention relates to flavanone derivatives, and preparation method and use thereof, particularly relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, a preparation method thereof, and use thereof for preventing or treating a mental disorder or a nervous system disease. The compound of the invention exerts significant activity of inhibiting microglial activation and neuroinflammation, can antagonize dopamine D2 receptor, improve the ethological change in multiple animal models for mental disorders, effectively inhibit neuroinflammation and demyelination, and can be used to prevent or treat a mental disorder and a nervous system disease.

Abstract: A protein chip, kit and preparation method thereof for detecting abnormal decarboxy prothrombin in serum, a substrate carrier of the protein chip is provided with a plurality of detection subareas; wherein each detection subarea is used for detecting a serum sample, and is internally provided with a detection-spot area and a control-spot area, and the detection-spot area has a detection spot formed by spraying a trace amount of a DCP-specific antibody, the control-spot area has a control spot formed by spraying a bovine serum albumin; all the detection spots within one of the detection-spot area have the same material concentration, to form each of the detection spots, a total volume of 3-5 nl of the DCP-specific antibody with a concentration of 3-5 mg/mL is used; each of the detection spots is formed by a non-contact spotter, performing 6-10 spot sprays and spraying 300-500 pL in each spray.

Abstract: The invention relates to a poly(n-butyl cyanoacrylate) nanoparticle with dual modifications, a drug delivery system comprising the nanoparticle, and a method for preparing the nanoparticle or the drug delivery system. The nanoparticle is modified with a first modifier and a second modifier on the surface, the first modifier is a hydrophilic polymer, and the second modifier is an amino acid and/or a lipid. The invention further relates to a use of the nanoparticle in promoting drug penetration across the blood brain barrier in a subject.